Longboard Pharmaceuticals Announces FDA Granted Breakthrough Therapy Designation For Bexicaserin
Portfolio Pulse from Benzinga Newsdesk
Longboard Pharmaceuticals announced that the FDA has granted Breakthrough Therapy designation for bexicaserin, a treatment for seizures associated with Developmental and Epileptic Encephalopathies (DEEs).
July 01, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Longboard Pharmaceuticals received FDA Breakthrough Therapy designation for bexicaserin, which is aimed at treating seizures associated with DEEs. This designation could expedite the development and review process, potentially leading to faster market entry and increased investor confidence.
The FDA's Breakthrough Therapy designation is a significant milestone that can accelerate the development and review process of bexicaserin. This news is likely to boost investor confidence and positively impact LBPH's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100